Mediclinic International announces Dr Felicity Harvey as next Senior Independent Director

– SOUTH AFRICA, Stellenbosch –  Mediclinic International plc (LON: MDC), a leading international private healthcare services group, today announced the upcoming appointment of Dr Felicity Harvey as Senior Independent Director, succeeding Alan Grieve from 13 September 2021.

Alan Grieve and Trevor Petersen, both independent non-executive directors, informed the Board of their intention to retire as directors of the Company upon the conclusion of their second three-year term of appointment on 14 February 2022.

Messrs Grieve and Petersen will continue to serve on the Board in a non-independent capacity from 13 September 2021 until 14 February 2022.

In addition, with effect from 13 September 2021:

  • Mr Tom Singer will succeed Mr Grieve as Chair of the Audit & Risk Committee, and
  • Mr Steve Weiner will succeed Mr Petersen as Chair of the Remuneration Committee.

Messrs Grieve and Petersen will step down from all Board committees with effect from 13 September 2021.

Mediclinic’s Chair, Dame Inga Beale commented: “On behalf of the Board, I would like to thank Alan and Trevor for their commitment and valued contributions to the Board and the Group over many years. We are using the opportunity afforded by their retirements to further refresh and strengthen the Board. I wholeheartedly welcome Felicity’s appointment as Senior Independent Director, Tom’s appointment as Chair of the Audit and Risk Committee and Steve becoming Chair of the Remuneration Committee”.

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa and the United Arab Emirates.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 31 March 2021, Mediclinic comprised 74 hospitals, five sub-acute hospitals, two mental health facilities, 18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day case clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three of which in Namibia), five sub-acute hospitals, two mental health facilities and 12 day case clinics (four of which operated by Intercare) across South Africa, and around 8 600 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid-2022.

The Company’s primary listing is on the London Stock Exchange in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For more information : https://www.mediclinic.com/en

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.